ProShare Advisors LLC Acquires 10,976 Shares of Edwards Lifesciences Corporation $EW

ProShare Advisors LLC lifted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 11.6% during the 2nd quarter, Holdings Channel.com reports. The firm owned 105,944 shares of the medical research company’s stock after purchasing an additional 10,976 shares during the period. ProShare Advisors LLC’s holdings in Edwards Lifesciences were worth $8,286,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Future Fund LLC lifted its position in Edwards Lifesciences by 11.7% during the 2nd quarter. Future Fund LLC now owns 22,585 shares of the medical research company’s stock worth $1,766,000 after buying an additional 2,373 shares in the last quarter. Midwest Trust Co bought a new position in shares of Edwards Lifesciences in the second quarter worth about $263,000. Acadian Asset Management LLC lifted its position in shares of Edwards Lifesciences by 236.5% during the second quarter. Acadian Asset Management LLC now owns 450,996 shares of the medical research company’s stock worth $35,264,000 after purchasing an additional 316,977 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new stake in shares of Edwards Lifesciences during the second quarter valued at approximately $1,622,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Edwards Lifesciences in the second quarter valued at approximately $3,800,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Up 0.5%

Edwards Lifesciences stock opened at $85.55 on Thursday. The firm has a market capitalization of $49.65 billion, a price-to-earnings ratio of 12.31, a PEG ratio of 3.97 and a beta of 1.03. The company’s 50 day simple moving average is $77.99 and its 200 day simple moving average is $77.59. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. Edwards Lifesciences Corporation has a fifty-two week low of $65.31 and a fifty-two week high of $87.09.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.08. The company had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same period last year, the business posted $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,020 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,816,265.10. The trade was a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 22,970 shares of company stock worth $1,862,878. Corporate insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the topic of several research reports. Barclays reaffirmed an “overweight” rating and set a $99.00 price objective (up previously from $95.00) on shares of Edwards Lifesciences in a report on Friday, October 31st. National Bankshares set a $92.00 price target on Edwards Lifesciences in a research note on Friday, October 31st. The Goldman Sachs Group set a $104.00 price objective on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Friday, October 31st. Sanford C. Bernstein reissued a “market perform” rating and set a $90.00 price objective on shares of Edwards Lifesciences in a report on Monday, November 3rd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday, October 8th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $91.39.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.